ClinicalTrials.Veeva
Menu

Find clinical trials for Colon Cancer in Baltimore, MD

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Colorectal Cancer
Colonic Cancer
Cancer
Non-Small-Cell Lung Carcinoma
Lung Cancer
Neoplasm Metastasis
Adenocarcinoma

Colon Cancer trials near Baltimore, MD, USA:

Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer (AZUR-2)

(SOC) in participants with untreated T4N0 or Stage III (resectable), defective mismatch repair/ microsatellite instability high (dMMR/MSI-H) colon...

Enrolling
Colonic Neoplasms
Neoplasms, Colon
Drug: CAPEOX
Biological: Dostarlimab

Phase 3

GlaxoSmithKline (GSK)
GlaxoSmithKline (GSK)

Bethesda, Maryland, United States and 250 other locations

A phase I/II study of PI3Kinase inhibition (copanlisib) and anti-PD-1 antibody nivolumab in relapsed/refractory solid tumors with expansions....

Active, not recruiting
Colon Cancer
Unresectable or Metastatic Microsatellite Stable (MSS) Solid Tumor Along With Microsatellite Stable (MSS) Colon Cancer
Drug: Nivolumab
Drug: Copanlisib

Phase 1, Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

(PK) of BBO-8520, a KRAS G12C (ON) inhibitor, single agent and in combination with pembrolizumab in patients with advanced non-small cell lung cancer...

Enrolling
Colon Cancer
Metastatic Colon Cancer
Drug: BBO-8520
Drug: Pembrolizumab

Phase 1

TheRas, Inc., d/b/a BridgeBio Oncology Therapeutics

Fairfax, Virginia, United States and 14 other locations

or metastatic mismatch repair-proficient (MMR-p) colorectal cancer (mCRC) or unresectable or metastatic MMR-p pancreatic ductal adenocarcino...

Enrolling
Pancreatic Cancer
Colorectal Cancer
Drug: KRAS Vaccine with Poly-ICLC adjuvant
Drug: Botensilimab

Phase 1

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors, including but not limited to cholangiocarcinoma, chondrosarcoma, an...

Active, not recruiting
Any Solid Tumor
Glioma
Drug: LY3410738
Drug: Gemcitabine

Phase 1

Lilly
Lilly

Baltimore, Maryland, United States and 32 other locations

is to evaluate the safety and tolerability of RMC-9805 as monotherapy and in combination with RMC-6236 in adults with KRAS G12D-mutant solid tumors...

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236
Drug: RMC-9805

Phase 1

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 16 other locations

This is an open-label, first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor ...

Active, not recruiting
Any Solid Tumor
Colon Cancer
Drug: LOXO-292

Phase 1, Phase 2

Loxo Oncology
Loxo Oncology

Baltimore, Maryland, United States and 83 other locations

Evaluate the safety and tolerability of RMC-6236 in adults with specific RAS mutant advanced solid tumors....

Enrolling
Non-small Cell Lung Cancer (NSCLC)
Colorectal Cancer (CRC)
Drug: RMC-6236

Phase 1

Revolution Medicines
Revolution Medicines

Baltimore, Maryland, United States and 15 other locations

This first-in-human study will evaluate safety, tolerability, anti-tumor activity, immunogenicity, pharmacokinetics and pharmacodynamics of ....

Enrolling
Advanced Cancer
Endometrial Cancer
Drug: PHN-010

Phase 1

Pheon Therapeutics

Fairfax, Virginia, United States and 4 other locations

safety and clinical activity of nivolumab and relatlimab in patients with metastatic or locally advanced microsatellite stable (MSS) colorectal cancer...

Active, not recruiting
Colorectal Adenocarcinoma
Microsatellite Stable (MSS) Colorectal Adenocarcinomas
Drug: Relatlimab
Drug: Nivolumab

Phase 2

Johns Hopkins Medicine
Johns Hopkins Medicine

Baltimore, Maryland, United States

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems